The global bipolar disorders treatment market is expected to grow significantly over the forecast period. The global market was valued at USD 5600 million in 2018 and is projected to grow with 2.9% CAGR over the forecast period.
Bipolar disorder is a manic-depressive disorder, which is a type of mental illness. It is characterized by mood swings and mood episodes appear during the illness. Manic and depressive episodes are common mood episodes observed in bipolar disorders. The government initiatives for treatment of bipolar disorders, advancement in combination drugs, and growing demand for antidepressant drugs are expected to drive the growth of the market. Moreover, growing research and development activities conducted by government and nonprofit organizations are contributing to the growth of the market. For instance, Harvard University started Harvard brain science initiative (HBI) for R&D on bipolar disorders. This program has provided USD 3 million in funds to the research and development related to bipolar disorders.
The side effects associated with therapy, low diagnosis rate, and dearth of experts may hamper the growth of the global market during the assessment period.
Segmentation
The global bipolar disorders and treatment market has been segmented on the basis of drug class, mechanism of action, and end user.
Based on drug type, the global market has been classified into mood stabilizer, antipsychotic drugs, antianxiety drugs, antidepressant drugs, anticonvulsants, and others.
Based on the mechanism of action, the global market has been segmented into selective serotonin reuptake inhibitor, serotonin norepinephrine reuptake inhibitor, monoamine oxidase inhibitors, beta-blockers, tricyclic antidepressant drug, and others.
The global market, by end user, has been segmented into hospitals and clinics, multispecialty centers, and others.
The bipolar disorders treatment market has been segmented, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa.
The bipolar disorders treatment market in the Americas has further been segmented into North America and Latin America, with the North American market divided into the US and Canada.
The European bipolar disorders treatment market has been bifurcated into Western Europe and Eastern Europe. Western Europe has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe.
The bipolar disorders treatment market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The bipolar disorders treatment market in the Middle East & Africa has been segmented into the Middle East and Africa.
Key Players
Allergan (Ireland), AstraZeneca (UK), Eli Lilly and Company(US), GlaxoSmithKline(UK), Abbott (US), Bristol-Myers Squibb (US), Johnson & Johnson (US), Pfizer Inc. (US), Cephalon Inc. (US), Otsuka America Pharmaceutical Inc. (US), and Gedeon Richter plc (Hungary) are some of the key players operating in the global bipolar disorders treatment market.
Global Bipolar Disorders Treatment Market, by Drug Type
- Mood Stabilizer
- Antipsychotic Drugs
- Antianxiety Drugs
- Antidepressant drugs
- Anticonvulsants
- Others
Global Bipolar Disorders Treatment Market, by Mechanism of Action
- Selective Serotonin Reuptake Inhibitor
- Serotonin Norepinephrine Reuptake Inhibitor
- Monoamine Oxidase Inhibitors
- Beta-Blockers
- Tricyclic Antidepressant Drug
- Others
Global Bipolar Disorders Treatment Market, by End User
- Hospitals and Clinics
- Multispecialty Centres
- Others
Request Customization
Get a Sample
Get a Sample
Request Customization